Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors Article Open access 05 August 2023 The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy Article Open access 06 May 20...
Resistance to PD-1/PD-L1 blockade therapy Checkpoint inhibitors targeting PD-1 or PD-L1 could disturb the interaction between PD-1 and PD-L1, which would preserve anti-tumor properties of T cells, withdraw immune escape, and normalize their ability to induce tumor cell death. Currently, PD-...
[9] Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance[J]. Nat Immunol, 2022,23(5):660-670. [10] Sendur MAN. A...
4.Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37(4):443-455. doi:10.1016/j.ccell.2020.03.017 6.Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic N...
MacDonagh L, Gray SG, Breen E, et al. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Lett 2018;428:117-26. [Crossref] [PubMed] Liu M, Wu H, Xu C. Targeting cancer stem cell pathways for lung cancer therapy. Curr Opin Oncol 2023;35:78-85. [Cros...
3.Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288-2301. doi:10.1056/NEJMoa1716948 4.Schoenfeld AJ, Hellmann MD. Acquired Resistance to Immune Checkpoint Inhibitors. Cancer Cell. 2020;37(4...
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine The rym3 (formerly designated ym3) gene conferring resistance to barley yellow mosaic virus (BaYMV) is effective against all strains of the virus bu...
Immunotherapy utilizing immune checkpoint inhibitors(ICIs) such as antibodies targeted to programmed cell death1 (PD-1) have been established as an essential treatmentagainst cancer. However, tumor intrinsic and acquiredresist...
Perspectives on Acquired Resistance to PD-1 AxisInhibitors in Patients with Non–Small Cell LungCancer Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 Patients with advanced non-small cell lung cancer. J Thorac Oncol. ... T Diane,SK Padda,HA Wakelee - 《...
[8]Siu LL, Wang D, Hilton J, et al. First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors[J]. Clin Cancer Res, 2022, ...